These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2680288)

  • 1. Comparative study of bezafibrate and probucol in hyperlipidaemia.
    Páez Moreno JP; González G
    Curr Med Res Opin; 1989; 11(8):523-32. PubMed ID: 2680288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of probucol and benzafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits.
    Ou J; Saku K; Jimi S; Liao YL; Ohta T; Zhang B; Arakawa K
    Jpn Circ J; 1999 Jun; 63(6):471-7. PubMed ID: 10406588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of probucol on hyperlipidemic patients with cardiac allografts.
    Anderson JL; Schroeder JS
    J Cardiovasc Pharmacol; 1979; 1(3):353-65. PubMed ID: 94402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Iida H; Izumino K; Asaka M; Fujita M; Nishino A; Sasayama S
    Nephron; 1987; 47(4):280-3. PubMed ID: 3696330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
    Am J Cardiol; 1990 Sep; 66(8):22B-30B. PubMed ID: 2206033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
    Saku K; Zhang B; Jimi S; Bai H; Hirata K; Sasaki N; Liu R; Arakawa K
    Eur J Clin Pharmacol; 1995; 48(3-4):209-15. PubMed ID: 7589043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probucol (Lorelco) in treatment of hyperlipemia.
    Murphy BF
    JAMA; 1977 Dec; 238(23):2537-8. PubMed ID: 199758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
    Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
    Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of probucol in hyperlipidemic patients during two years of administration.
    Parsons WB
    Am Heart J; 1978 Aug; 96(2):213-7. PubMed ID: 354360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
    LeLorier J; DuBreuil-Quidoz S; Lussier-Cacan S; Huang YS; Davignon J
    Arch Intern Med; 1977 Oct; 137(10):1429-34. PubMed ID: 335998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probucol in hypercholesterolemia. A double blind study.
    Riesen WF; Keller M; Mordasini R
    Atherosclerosis; 1980 Jun; 36(2):201-7. PubMed ID: 7406949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
    Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
    Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
    Heller F; Harvengt C
    Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Atherosclerosis; 1980 Nov; 37(3):469-74. PubMed ID: 7458992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose colestipol plus probucol for hypercholesterolemia.
    Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H
    Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term effects of probucol on serum lipid levels.
    McCaughan D
    Arch Intern Med; 1981 Oct; 141(11):1428-32. PubMed ID: 7025778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
    Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
    Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year experience with probucol, a new hypocholesterolaemic agent.
    Ng AS; Johan A; Quek SS; Tan IK
    Singapore Med J; 1982 Aug; 23(4):191-3. PubMed ID: 7178901
    [No Abstract]   [Full Text] [Related]  

  • 20. Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.
    Salel AF; Zelis R; Sodhi HS; Price J; Mason DT
    Clin Pharmacol Ther; 1976 Dec; 20(6):690-4. PubMed ID: 186224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.